title: HIV/AIDS eradication.
abstract: Antiretroviral therapy can inhibit HIV replication in patients and prevent progression to AIDS. However, it is not curative. Here we provide an overview of what antiretroviral drugs do and how the virus persists during therapy in rare reservoirs, such as latently infected CD4+ T cells. We also outline several innovative methods that are currently under development to eradicate HIV from infected individuals. These strategies include gene therapy approaches intended to create an HIV-resistant immune system, and activation/elimination approaches directed towards flushing out latent virus. This latter approach could involve the use of novel chemically synthesized analogs of natural activating agents.
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Marsden
authors.forename: Jerome A
authors.initials: JA
authors.lastname: Zack
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D015316:Genetic Therapy; D006678:HIV / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D017735:Virus Latency / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000276:Adjuvants, Immunologic; D019380:Anti-HIV Agents; D014764:Viral Proteins